Ionis Pharma (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals concluded the fourth quarter of 2025 with a significant increase in cash and equivalents, totaling $2.67 billion, marking a rise from $2.24 billion at the end of the third quarter, indicative of robust financial health and liquidity. The company demonstrated strong revenue growth, particularly with the FCS drug Tryngolza, which achieved $50 million in quarterly sales—well above expectations—alongside promising developments in its other product launches, such as Wainua, which also exceeded revenue forecasts. With an optimistic projection of peak sales for Tryngolza being raised to $4.5 billion by 2036 and the ongoing momentum in various therapeutic areas, Ionis exhibits a strong potential for sustained growth moving into 2026 and beyond.

Ionis Pharmaceuticals is facing a challenging financial outlook as the company anticipates a "meaningful decline" in revenues from its drug Tryngolza in 2026, driven by a strategic shift in pricing from rare disease rates to more competitive pricing for a larger patient population. The company has reported accumulated significant losses with no expected path to profitability for several years, projecting total revenues of $800-825 million, which falls short of the consensus estimate of $914 million, alongside a non-GAAP operating loss of $500-550 million exceeding the consensus loss of $399 million. Additionally, ongoing risks such as slower market uptake, potential delays in regulatory approvals, and concerns about competitiveness in the hematology space hinder Ionis's growth potential and raise concerns for investors.